biostudies-literatureUnknown4(9)Mann C<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have improved outcomes for several malignancies, but cancer patients face an increased risk of cardiovascular disease due to shared risk factors, similar biological mechanisms, and cardiotoxic side effects of therapy. Effective risk stratification strategies are urgently needed.<h4>Objectives</h4>This study explored the association between the biomarkers with the risks of acute cardiovascular hospitalizations and death in cancer patients receiving ICI therapy.<h4>Methods</h4>We used electronic health records of patients treated with ICI who had available baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at Vienna General Hospital between January 2017 and July 2022. The primary outcome of interest was the composite oJACC. Advances102022https://www.ebi.ac.uk/biostudies/studies/S-EPMC12335986biostudies-literaturePrognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.PMC12335986Raderer MBergler-Klein JBraser AVHamidi FGerges CSpannbauer AGyongyosi MRiesenhuber MHulsmann MHengstenberg CMann CZelniker TAGottsauner-Wolf MPailer UfalsePrognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.<h4>Background</h4>Immune checkpoint inhibitors (ICIs) have improved outcomes for several malignancies, but cancer patients face an increased risk of cardiovascular disease due to shared risk factors, similar biological mechanisms, and cardiotoxic side effects of therapy. Effective risk stratification strategies are urgently needed.<h4>Objectives</h4>This study explored the association between the biomarkers with the risks of acute cardiovascular hospitalizations and death in cancer patients receiving ICI therapy.<h4>Methods</h4>We used electronic health records of patients treated with ICI who had available baseline N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels at Vienna General Hospital between January 2017 and July 2022. The primary outcome of interest was the composite o2025-01-01T00:00:00Z2025 Jul2026-04-16T15:09:05.404Z2026-04-07T14:12:24.564ZS-EPMC123359864074951610.1016/j.jacadv.2025.102022